Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × INCB057643 × Genitourinary × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡